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Abstract
This study examined whether insulin modulates the neurochemical effects of nicotine in the
mesolimbic pathway of diabetic rats. Rats received vehicle or streptozotocin (STZ) to induce
hypoinsulinemia. A subset of STZ-treated rats was implanted with insulin pellets that normalized
glucose levels. Two-weeks later, dialysis probes were implanted into the nucleus accumbens
(NAc) and ipsilateral ventral tegmental area (VTA). The next day, dialysate samples were
collected during baseline and then following systemic administration of nicotine. Samples were
also collected following intra-VTA administration of the gamma-aminobutyric acid (GABA)A
receptor antagonist, bicuculline. Dopamine, acetylcholine (ACh), GABA, and glutamate levels
were assessed using liquid chromatography/mass spectrometry (LC/MS). The results revealed that
vehicle-treated rats displayed a nicotine-induced increase in NAc dopamine. In contrast,
STZtreated rats did not display any changes in NAc dopamine following nicotine administration,
an effect that was likely related to a concomitant increase in GABA and decrease in glutamate
levels in both the NAc and VTA. Intra-VTA administration of bicuculine produced an increase in
NAc dopamine in vehicle-treated rats that was absent in STZ-treated rats. Vehicle-treated rats
displayed a nicotine-induced increase in ACh levels in the NAc (but not VTA), an effect that was
lower in the NAc of STZ-treated rats. Insulin supplementation normalized the neurochemical
effects of nicotine in the NAc and VTA of STZ-treated rats, suggesting that insulin modulates the
neurochemical effects of nicotine in the mesolimbic pathway of STZ-treated rats.
Keyword: tobacco use, diabetes, micro-dialysis, dopamine, amino acids, insulin
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Introduction
1.1 Tobacco use in a clinical setting
A major public health and economic concern is the high rates of tobacco use. According to
the Centers for Disease Control (CDC) and the World Health Organization (WHO), tobacco use
is the leading cause of preventable death and disease in the United States. With approximately 1.1
billion smokers worldwide, nearly 439,000 persons in the United States and 6 million people
worldwide experience tobacco-related deaths every year (CDC, 2016; WHO, 2011). The WHO
has predicted that by 2030, tobacco use will cause an estimated 9 million deaths per year (WHO,
2011). Approximately 16 million people in the United States live with a disease that is caused by
smoking, such as heart and/or cardiovascular disease and various types of cancer (CDC, 2016).
Although there are over 4,800 chemicals in tobacco, nicotine is the major habit-forming
compound in tobacco products (Balfour, 2004). Nicotine is a mild stimulant and when consumed
induces a feeling of euphoria, alertness, relaxation, and motor activation (Heishman et al., 2010;
Hukkanen et al., 2005; Le Foll & Goldberg, 2006, 2009). The addictive properties of nicotine are
believed to be one of the major motivating factors for continued smoking behavior despite its
harmful consequences (Balfour, 2004; Sohn et al., 2003; Mansvelder & McGehee, 2002). Indeed,
nicotine is readily self-administered by humans, dogs, rodents, and primates (Caille, 2012;
Corrigall, 1999; Harvey et al., 2004; Katner et al., 2004; Le Foll & Goldberg, 2006; 2009; Risner
et al., 1983). The recent rise in electronic nicotine delivery systems (i.e., ENDS) also speaks to the
strong reinforcing effects of this drug (Yoong et al., 2019; Drope et al., 2017).
Clinical studies have revealed that patients with diabetes display greater susceptibility to
tobacco use (Sattar el al., 2015; López et al., 2017). Specifically, persons with diabetes report
higher tobacco use and lower cessation rates than non-diabetic smokers (Bishop et al., 2009). There
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is also a greater incidence of negative affective states and depression during smoking abstinence
among patients with diabetes (Haire-Joshu et al., 1994; Spangler et al., 2006). Unfortunately,
tobacco use enhances the health complications associated with diabetes, including poorer glycemic
control and an increased risk of cardiovascular problems and mortality (Lycett et al. 2015;
Winhusen et al., 2019). Despite these problems, the underlying factors that motivate tobacco use
in this vulnerable population remain unclear. Rodent models are needed to address important
questions regarding the underlying mechanisms that promote tobacco use in patients with diabetes,
as described below.
1.2 Rodent models of diabetes
Various rodent preparations have been used to study how the behavioral effects of nicotine
are altered by diabetes. The most common rodent model of diabetes involves administration of
streptozotocin (STZ), a drug that is toxic to the insulin-producing β-cells in the pancreas (Lee et
al., 2010; Lenzen, 2008). STZ has high binding affinity for type 2 glucose transporters that are
prevalent in the pancreas. Following STZ administration, DNA methylation induces cellular
toxicity to the insulin-producing β-cells of the pancreas (Lenz, 2008). As a result, STZ produces a
permanent and rapid increase in blood glucose levels within 48 hrs of administration (Arison et
al., 1967; Lenzen, 2008; Cruz et al., 2019). The disruption of insulin systems and the resultant
increase in glucose levels mimics the etiology of Type 1 and later stages of Type 2 diabetes
(Akbarzadeh et al., 2007; Lee et al., 2010).
Prior work has assessed the rewarding effects of nicotine in rodent models of diabetes
involving STZ. Our initial work revealed that STZ-treated rats display greater nicotine-induced
conditioned place preference (CPP; Íbias et al., 2018; Pipkin et al., 2017) and intravenous selfadministration (IVSA; O’Dell et al., 2013) as compared to vehicle-treated controls. Subsequent
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studies revealed that the heightened rewarding effects of nicotine observed in STZ-treated rats are
insulin mediated. This was based on our finding that STZ-treated rats that received insulin
supplementation displayed similar nicotine-induced CPP (Íbias et al., 2018) and IVSA (Cruz et
al., 2019) as compared to vehicle-treated controls. These behavioral studies suggested that insulin
plays a key role in modulating the rewarding effects of nicotine. This work also raised important
questions regarding the underlying mechanisms by which insulin systems modulate the behavioral
effects of nicotine.
1.3 Mechanisms of nicotine in the mesolimbic pathway
Much work has established that the behavioral effects of nicotine are due to activation of
nicotinic acetylcholine receptors (nAChRs) in the brain. nAChRs consist of pentameric membrane
proteins of homomeric or heteromeric α or β receptor subunit complexes. In the presence of
nicotine, the various α or β nAChR subunits leads to distinct channel activation and/or
desensitization. It is well established that the rewarding effects of nicotine are due to the ability of
this drug to enhance dopamine transmission in the mesolimbic pathway. This pathway originates
in the ventral tegmental are (VTA) and terminates in several forebrain structures including the
nucleus accumbens (NAc; Koob, 2000; Koob & Kreek, 2007; Mansvelder et al., 2003). Figure 5
displays the mesolimbic pathway projections described here. Specifically, dopamine release in
the NAc is controlled by excitatory and inhibitory mechanisms locally and via modulation of the
dopamine cell bodies in the VTA. The control of dopamine release occurs via the amino acid
neurotransmitters gamma aminobutyric acid (GABA) and glutamate, which innervate dopamine
release in the mesolimbic pathway. Specifically, dopamine release in the NAc is suppressed by
local GABAergic interneurons that modulate dopamine terminals from the VTA. Dopamine
release in the NAc is enhanced via glutamatergic projections from the prefrontal cortex that
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enhance dopamine release from terminals arising from the VTA. The principal role of GABA is
to decrease neural excitability via opening of ion channels that allow the flow of negatively
charged chloride ions into the cell, which results in cellular depolarization. GABAergic inhibition
of dopamine transmission occurs through activation of GABA and GABA receptors located on
A

B

dopamine cell bodies in the VTA (Criswell et al., 1993; Cruz et al., 2004; Labouèbe et al., 2007;
Okada et al., 2004). On the other hand, glutamate enhances dopamine release via activation of
ionotropic receptors that produce excitatory electrical responses in their targets a fraction of a
millisecond after being stimulated. Glutamatergic stimulation of dopamine release occurs via
activation of NMDA and AMPA ionotropic receptors located on VTA dopamine cell bodies (Choi
et al., 2011; Johnson et al., 1992; Mao et al., 2011). Also, local dopamine release in the NAc is
controlled via glutamatergic ionotropic receptors that are activated via glutamatergic inputs from
the prefrontal cortex (Choi et al., 2011; Johnson et al., 1992; Mao et al., 2011).
With regard to how nicotine enhances dopamine release in the NAc, there are an array of
different nAChRs expressed on the GABAergic and glutamatergic inputs to the VTA that regulate
dopamine release in the mesolimbic pathway (Xu et al., 2006; Mansvelder & McGehee, 2002;
Johnson et al., 1992; Kalivas et al., 1989; Kalivas et al., 1993; Mansvelder et al., 2003). Dopamine
cell bodies in the VTA express α2-10 and β2-4 nAChRs subunits (Mansvelder et al., 2003).
GABAergic interneurons express α4β2 and glutamate terminals in the VTA express α7 nAChRs.
Following administration of nicotine, α4β2 sites on VTA GABA neurons quickly desensitize
(Mansvelder et al., 2002). As a result, VTA dopamine neurons receive less inhibition from GABA
due to the desensitization of α4β2 sites. This effect of nicotine produces a reduction in inhibitory
tone that results in enhanced activation of dopamine neurons. Nicotine also binds to α7 nAChRs
on glutamate terminals, and these receptors quickly sensitize following nicotine administration
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(Wooltorton et al., 2003). As a result, nicotine produces a shift in tonic inhibition towards
excitation of VTA dopamine neurons that results in enhanced dopamine transmission in the NAc.
Overall, desensitization of the α4β2 sites on VTA GABA neurons leads to disinhibition of
dopamine neurons thereby facilitating a more sustained increase in the release of dopamine in the
NAc following nicotine administration.
1.4 Prior work that provided the foundation for this Dissertation
Previous studies that were conducted for my Master’s thesis established that the enhanced
rewarding effects of nicotine in STZ-treated rats is insulin mediated. Specifically, we demonstrated
that STZ-treated rats that received insulin supplementation displayed “normal” levels of nicotine
intake similar to control rats (Cruz et al., 2019). The latter report also revealed that insulinassociated metabolic peptides including insulin, leptin, amylin, and glucagon peptide-like 1 (GLP1) are disrupted in STZ-treated rats. Importantly, we observed that these metabolic peptide changes
were normalized to control levels in STZ-treated rats that received insulin supplementation. Work
in my Master’s thesis also revealed that STZ administration lowered insulin receptor substrate-2
(IRS-2) and insulin growth factor-like 1 receptor β (IGF-1Rβ) in the NAc (but not the VTA), an
effect that was normalized in the NAc to control levels following insulin supplementation.
Together, this work suggested that a lack of insulin modulates the neurochemical effects of
nicotine in a region-specific manner. However, the mechanisms by which insulin modulates
dopamine release in the mesolimbic pathway remain unclear.
1.5 Dissertation goals and hypotheses
The overall goal of this dissertation was to assess the role of insulin in modulating the
neurochemical effects of nicotine in the mesolimbic pathway of diabetic rats. A sub-goal was to
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assess whether insulin modulates the neurochemical effects of nicotine via amino acid regulation
of dopamine release in the mesolimbic pathway.
Aim 1 assessed whether insulin modulates nicotine-induced dopamine release in the
mesolimbic pathway of STZ-treated rats. We first compared dopamine release following nicotine
administration in the NAc and VTA of vehicle- and STZ-treated rats. To examine the role of
insulin, a group of STZ-treated rats were treated with insulin immediately after STZ
administration. Two-weeks later, dialysate levels of dopamine were assessed in the NAc and VTA
during baseline and following systemic administration of nicotine. It was hypothesized that
dopamine release would be suppressed in the VTA and NAc of STZ-treated rats as compared to
controls. Also, it was hypothesized that insulin supplementation would restore the suppression of
nicotine-induced dopamine release in both the NAc and VTA of STZ-treated rats. The rationale
for our hypotheses is based on previous work showing that the increase in nicotine-induced
dopamine release in the NAc is absent in STZ-treated rats (O’Dell et al., 2013). The latter study
also revealed that STZ-treated rats display more dopamine transporters (DAT) in the NAc, which
may reflect greater dopamine clearance in the NAc of STZ-treated rats.
Aim 2 assessed whether insulin modulates nicotine-induced dopamine release in the
mesolimbic pathway via amino acids and cholinergic systems. We compared GABA, glutamate,
and ACh levels following nicotine administration in the NAc and VTA of vehicle- and STZ-treated
rats. To examine the role of insulin, a group of STZ-treated rats were also treated with insulin
immediately after STZ administration. Two-weeks later, dialysate levels of GABA, glutamate, and
ACh were assessed in the NAc and VTA of these groups during baseline and following systemic
administration of nicotine. Our sample analysis was obtained from the same rats from Aim 1. It
was hypothesized that the suppression of dopamine release would be due to an increase in
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inhibitory GABA release and a decrease in excitatory glutamate release in the NAc and VTA of
STZ-treated rats. It was also hypothesized that insulin supplementation would restore the
neurochemical effects of nicotine via amino acid control of dopamine release in the mesolimbic
pathway (Koob, 2000; Koob and Kreek, 2007; Scofield et al., 2016; Kalivas, 2009). With regard
to ACh, it was hypothesized that ACh release would be reduced in the NAc and VTA of STZtreated rats following nicotine administration, an effect that we expected to also be restored by
insulin supplementation. The rationale for Aim 2 was based on previous work showing intra-NAc
administration of insulin enhances local dopamine and glutamate release (Labouèbe et al., 2013;
Oginsky et al., 2019). Another report revealed that systemic administration of insulin increased
dopamine release in NAc via activation of insulin receptors on striatal ACh interneurons (Stouffer
et al., 2015). Studying the manner in which insulin regulates mesolimbic dopamine transmission
is important towards understanding how a lack of insulin signaling alters the behavioral effects of
nicotine in STZ-treated rats.
1.6 Background information on neurochemical methods
Analyzing neurotransmitter content dynamics is an important method in neuroscience
research. In vivo microdialysis procedures allow an experimenter to estimate changes in levels of
neurotransmitters in the synaptic space of a discrete brain region. Using a stereotactic apparatus, a
probe is inserted into the brain region of interest.
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The schematic above depicts a microdialysis probe, which consists of a semi-permeable
membrane tip attached to the edge of a cannula (adapted from Chaurasia et al., 2007).
A buffer made of artificial cerebrospinal fluid (aCSF) is infused through the inlet of the
probe at a constant rate via a syringe pump. The infusion of “clean” aCSF perfusate creates a
concentration gradient across the microdialysis membrane allowing for small molecules to enter
the membrane surface via diffusion properties. The dialysate is collected in a vial from a line
attached to the outlet of the probe. The dialysate contains the neurotransmitters of interest to be
analyzed later. The passage of molecules across the membrane tip is influenced by changes in the
concentration of neurotransmitters in the brain, the flow rate of the perfusate, and the size of the
pores on the membrane tip. Typically, the external diameter of the membrane is about 250-300 µm
with a molecular weight limit to capture between 6,000-20,000 Daltons. In this Dissertation,
dialysate samples were collected from both the NAc and VTA to estimate nicotine-induced
changes in synaptic levels of dopamine, GABA, glutamate, and ACh.
Different methods have been used to measure neurotransmitter content in dialysate
samples. These assays include high performance liquid chromatography (HPLC) electrochemical
detection, HPLC-fluorescence detection, capillary electrophoresis-laser induced fluorescence, and
immunoassays. A limitation with some of these methods is that they only measure one
neurotransmitter at a time and they lack sensitivity for detecting small chaanges in neurotransmitter
levels. This can be limiting when trying to study dynamic changes and relationships among
different neurotransmitter systems in brain regions where the content of these analytes is low.
Thus, the present work employed liquid chromatography mass spectrometry (LC/MS) methods to
test the hypothesis of Aims 1 and 2. The rationale for using LC/MS is related to the high level of
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sensitivity of the MS system and its ability to assess an array of neurotransmitters in a single
dialysate sample.

9

Chapter 2: Materials & Methods
2.1 Subjects
Adult male Wistar rats were obtained from an out-bred stock of rats (Envigo Inc;
RRID:RGD_13508588) that were maintained on a regular 12-hr light/dark cycle (lights off at 6:00
PM and on at 6:00 AM) in a humidity- and temperature- controlled vivarium (22 C). The rats were
◦

single housed in standard ventilated hanging cages (41.5 cm long × 17 cm wide × 21 cm high).
Starting between postnatal day (PND) 52-60, the rats were handled and weighed for at least 3-5
days. The rats weighed between 300-350 grams at the start of the experiments prior to STZ
administration. The rats had ad libitum access to food and water throughout the study. All
procedures were approved by The University of Texas at El Paso Institutional Animal Care and
Use Committee, and the 2011 Guide for Care and Use of Laboratory Animals (Institute of
Laboratory, Animals Resources on Life Sciences, the National Research Council, and the National
Academy of Sciences; reference number: A-201902-01). Although our hypotheses were not preregistered or our sample size predetermined by statistical test, the experimental procedures, sample
size, and statistical approach used in this report were based on prior published works (Cruz et al.,
2019; Carcoba et al., 2018; O’Dell et al., 2013). The experimental groups consisted of rats that
were randomly selected from a fully out-bred line of animals. Simple randomization for treatment
conditions occurred prior to the start of the experiment via a number labeling system for each rat.
Then, the animals were arbitrarily assigned to different treatment groups. The experimenters were
blinded to the subjects’ treatment condition during dialysis testing and the sample preparation for
the analysis of neurotransmitter content. Thus, blinding was achieved by only allowing
experimenters to know the rat number, but not their treatment group assignment.
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2.2 Procedural summary
The diagram below depicts the experimental timeline and dialysis testing procedures for this
Dissertation.

This study employed dual probe dialysis procedures to compare nicotine-induced changes
in neurotransmitter release in the NAc and VTA of vehicle- and STZ-treated rats. A group of rats
were supplemented with insulin pellets immediately after STZ administration. Changes in plasma
glucose levels and body weight were assessed throughout the study. Two-weeks after STZ
administration, nicotine-induced changes in dopamine, GABA, glutamate, and ACh were assessed
in dialysate collected from the NAc and VTA using LC/MS methods. At the end of testing,
neurochemical changes were assessed following intra-VTA administration of the GABA receptor
A

antagonist, bicuculline. This manipulation was included as a neurochemical control that produces
a robust increase in NAc dopamine levels and allowed us to assess group differences in
GABAergic control of downstream changes in NAc dopamine levels (see O’Dell and Parsons,
2004). Indeed, previous work has demonstrated that intra-VTA administration of bicuculline
produces strong ipsilateral turning, which provides evidence of correct probe placement in the
small region of the VTA (Grubb et al 2002; Westerink et al 1996). The schematic below illustrates
the group size for each neurotransmitter. The final analysis only included rats for which dopamine
was assessed in both the VTA and NAc. For some amino acids, our analyses included fewer
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samples than dopamine due to technical challenges associated with MS analysis of GABA and
glutamate in rat brain dialysate (Carcoba et al., 2018).

2.3 Diabetes induction and insulin supplementation
Rats received vehicle or STZ administration (45 mg/kg, s.c.). STZ was prepared
immediately prior to administration and was dissolved in 0.1M sodium citrate buffer pH 6.0
(Sigma-Aldrich, St. Louis, MO, USA; catalogue number: S0130). The dose of STZ was selected
based on previous work demonstrating that this concentration produces a reliable and long-lasting
increase in glucose levels in adult male Wistar rats (Cruz et al., 2019; O’Dell et al., 2013).
Immediately after vehicle or STZ administration, the rats were anesthetized with an
isoflurane/oxygen vapor mixture (1-3%). They then received a sham surgery or were prepared
subcutaneously with 2 insulin pellets based on the manufacturer specifications for the weight range
of the rats in this study (Linplant Toronto, ONT, CA; catalogue number: LHR-10BV). To
®

minimize discomfort, the rats received an injection of the analgesic, flunixin prior to and the day
after surgery (2.5 mg/kg; SC; catalogue number: NDC 11695-4012-1). The rats also received
topical application of lidocaine and Neosporin at the incision site (Henry Schein, Melville, NY,
®

USA). Each pellet releases 2 units of insulin per 24 hrs for at least 60 days. Glucose levels were
assessed every other day using a glucose meter calibrated for rodent blood (AlphaTRAK Abbott
®
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Park, IL, USA). A lancet was used to prick the tip of the tail to extract a small drop of blood that
was placed on a test strip. STZ-treated rats had to display glucose levels within 250-650 mg/dL in
order to proceed in the study (see Figure 1). Lastly, STZ-treated rats that received insulin
displayed a healthy range of glucose levels that were lower than 250 mg/dL. Three rats were
eliminated from the study that displayed glucose levels higher than 650 mg/dL.
2.4 Dialysis testing
Two-weeks after vehicle or STZ administration, the rats were re-anesthetized with an
isoflurane/oxygen vapor mixture (1-3%). They were then implanted with dialysis probes (Model
CMA 11, Holliston, MA, USA; catalogue number: CMA8309581) in the NAc and VTA (1- or 2mm membrane length, respectively). The probes were implanted using the following coordinates
from bregma for the NAc (AP = +1.7, ML = ±1.4, DV = −8.1) and VTA (AP = −4.8, ML = ±0.8,
DV = −8.5) using the rat brain atlas of Paxinos and Watson (2004). Following surgery, the rats
were transferred to a Plexiglas cage (24 cm long × 24 cm wide × 31 cm high) with food and water
Ⓡ

available throughout dialysis testing. Their probes were perfused with artificial cerebrospinal fluid
(aCSF; 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM d-glucose, and 0.25
mM ascorbic acid) that was dissolved in HPLC-grade water and adjusted to a pH of 7.4. The probes
were perfused with aCSF for at least 1 hr prior to probe placements at a rate of 1.0 μL/min. After
placement, the probes were allowed to perfuse overnight with aCSF at a rate of 1.0 μL/min. The
following day, the flow rate for the NAc was adjusted to 0.6 μL/min and the VTA probe was
adjusted to 1.1 μL/min for 1 hr prior to dialysate collection. Baseline samples were then collected
in 20-min intervals for 1 hr. Dialysate levels were then collected for 5 20-min sampling periods
following administration of 3 doses of nicotine in increasing order (0.3 mg/kg, 0.6 mg/kg, then 0.9
mg/kg; SC). (-) Nicotine hydrogen ditartrate (NIDA, Research Triangle, Bethesda, MA, USA;
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catalogue number: NICT-015) was dissolved in 0.9% sterile saline and adjusted to a pH level of
approximately 7.4. All nicotine solutions were prepared according to the rats’ body weight on the
day of dialysis testing. For the last series of dialysate samples, bicuculline (Sigma-Aldrich, St.
Louis, MO; catalogue number: B7686) was infused into the VTA probe (100 μM) and dialysate
was collected for 3 additional 20-min sampling periods. The dialysate samples were immediately
frozen on dry ice and then stored at −80 °C until assayed.
2.5 Probe placement verification
At the end of dialysis testing, the rats were sacrificed using CO2 inhalation and then
decapitated to ensure euthanasia. The probes were then extracted and the brains were removed,
frozen, and sliced in 10 μm coronal sections. Our estimates of the probe placements were
superimposed on digital images derived from the Paxinos and Watson atlas (2004). The schematic
below illustrates our probe placements in the NAc and VTA of vehicle-treated (white probe tip),
STZ-treated (black probe tip), and STZ-treated+insulin rats (gray probe tip). Each line reflects our
estimate of the placement of the membrane sampling portion of the probe collected during
sectioning. The left panel reflects placements in the NAc (2 mm in length), and the right panel
reflects placements in the VTA (1 mm in length). The diameter of the probe membrane was 0.24
mm wide, such that the estimated drawings of the probe span a range of sections wider than what
is noted on a single plate in the diagram. This schematic illustrates that our probe placements were
contained in the NAc and VTA.
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2.6 Neurotransmitter detection methods
Stock solutions of each neurotransmitter were prepared in MS grade water and kept at −80
°C. The standard mixture was diluted from stock solutions using aCSF from the dialysis test day.
Calibration curves were made using standard concentrations in a range of 5, 50, 100, 500, 1000
nM (GABA and glutamate) and 1, 5, 10, 25, 50 nM (dopamine and ACh). The internal standard
preparation and sample derivatization procedures followed the methods described in Song et al
(2012). Quantification of neurotransmitters in dialysate samples was performed by LC/MS
analysis. The neurochemical analyses were performed using a Thermo Scientific UltiMate™ 3000
Standard Quaternary System with a Waters BEH C18 column (1 mm × 100 mm, 1.7 μm, 130 Å
pore size) for separation. The autosampler was coupled to a TSQ Endura triple quadrupole MS.
The peaks were visually inspected to detect peak and artifacts. Standard curves were used to
calculate the concentration of all neurotransmitters in each sample.
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2.7 Statistics
For the analyses of glucose levels and body weight, separate 2-way mixed-model repeated
measures analysis of variance (ANOVA) were used with treatment group (vehicle, STZ-, and STZtreated+insulin) as a between-subject factor and time (days) as a within-subject factor. For the
neurochemical analyses, each neurotransmitter was analyzed separately in the NAc and VTA.
Separate analyses were used to compare group differences in baseline and nicotine-induced
changes across time. The first level of analysis compared baseline levels using 1-way ANOVAs
with treatment group (vehicle-, STZ-, and STZ-treated+insulin) as a between subject factor. The
second level of analysis compared changes across time using 2-way mixed-model repeatedmeasures ANOVAs with treatment group (vehicle-, STZ-, and STZ-treated+insulin) as a between
subject factor and time (20-min sampling periods) as a within-subject factor. The third level of
analysis compared group differences across time with the data collapsed across baseline versus
post-nicotine samples. For the repeated measures analyses with more than 3 levels, a test for the
assumption of normality was employed using the Mauchly Sphericity test. In cases where
violations of normality occurred, a Huynh–Feldt correction factor modified the degrees of freedom
which resulted in more accurate F-ratios. Where significant main or interaction effects were
observed, post-hoc analyses were conducted using protected Fisher’s least significant difference
test (p<0.05). All statistical analyses were performed on SPSS version 26, and all of the graphs
were generated using GraphPad Prism version 8.
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Chapter 3: Results
3.1 Baseline neurotransmitter levels
Table 1 illustrates baseline neurotransmitter levels (nM±SEM) in the NAc and VTA of
vehicle-, STZ-, and STZ-treated+insulin rats. The analysis of the NAc revealed that there were no
differences between treatment groups in baseline levels of dopamine [F(2,27)=1.72, p=0.19], GABA
[F(2,27)=2.29, p=0.12], or glutamate [F(2,19)=2.86, p=0.08]. There was a significant difference
between treatment groups in baseline levels of ACh [F(2,25)=4.45, p=0.02], with STZ-treated rats
displaying lower baseline ACh levels than STZ-treated+insulin rats (#p<0.05). The analysis of the
VTA revealed a significant difference across treatment groups in baseline levels of dopamine
[F(2,27)=7.09, p=0.003], GABA [F(2,24)=14.60, p=0.001], and glutamate [F(2,20)=8.81, p=0.02].
Specifically, STZ-treated rats displayed lower baseline levels of dopamine and glutamate and
higher levels of GABA relative to vehicle- and STZ-treated+insulin rats (†p<0.05). However, there
were no differences across treatment groups in baseline levels of ACh [F(2,25)=0.80, p=0.45].
Within the VTA, insulin supplementation appeared to have restored the STZ-induced changes in
baseline levels of dopamine, GABA, and glutamate, as there were no baseline differences in these
neurotransmitters across vehicle- and STZ-treated+insulin rats.
3.2 Body weight and glucose levels
Figure 1 illustrates mean body weight (g±SEM) and glucose levels (dL±SEM) across days.
The analysis revealed a significant group by day interaction for body weight [F(8.38,113.21)=13.63,
p=0.0001] and glucose levels [F(10.21,137.95)=27.62, p=0.0001]. STZ-treated rats displayed lower
body weight on days 9-17 relative to vehicle- and STZ-treated+insulin rats (†p<0.05). Also, STZtreated rats displayed significantly higher glucose levels on days 3-17 relative to both vehicle- and
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STZ-treated+insulin groups of rats (†p<0.05). There were no significant differences in body
weight and glucose levels between vehicle- and STZ-treated+insulin groups.
3.3 Neurotransmitter levels in the NAc
Figure 2 illustrates mean neurotransmitter levels (nM±SEM) in the NAc across time (left
panels) and collapsed across baseline and post-nicotine samples (right panels). The analysis of
NAc dopamine levels across time revealed a treatment group by time interaction [F(15.21,
205.42)=1.83,

p=0.03], with STZ-treated rats displaying a significant decrease in dopamine levels

during the 100-, 180-, 200-, 260-, 280-, 320-, and 360-min sampling periods relative to vehicleand STZ-treated+insulin rats (†p<0.05). STZ-treated rats also displayed a significant decrease in
dopamine levels during the 240- and 300-min sampling periods relative to vehicle-treated rats
(*p<0.05). This decrease in dopamine was also significant during the 80-, 160- and 340-min
sampling period relative to STZ-treated+insulin rats (#p<0.05). The analysis of dopamine levels
in the right panel revealed an interaction between treatment group and sampling condition
(baseline versus post-nicotine) [F(2,27)=3.60, p=0.04], with nicotine producing an increase in
dopamine levels relative to baseline in vehicle- and STZ-treated+insulin rats (ꞵp<0.05). Also,
STZ-treated rats displayed lower levels of dopamine relative to vehicle- and STZ-treated+insulin
rats post-nicotine administration (†p<0.05).
Subsequent analyses of changes in neurotransmitter levels across time revealed that there
were no interaction effects between treatment group and time for GABA [F(10.46,

141.25)=0.68,

p=0.75], glutamate [F(14.74, 140.04)=0.94, p=0.51], and ACh [F(20.84,260.52)=1.32, p=0.160]. There were
significant main effects of treatment group in the analysis of GABA [F(2,27)=3.87,
p=0.03], glutamate [F(2,19)=3.64, p=0.04], and ACh [F(2,25)=9.35, p=0.001]. Specifically, STZtreated rats displayed lower levels of glutamate and ACh, but higher levels of GABA relative to
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both vehicle- and STZ-treated+insulin rats (†p<0.05). Separate analyses of neurotransmitter levels
in the right panels revealed that there was no interaction between treatment group by sampling
condition (baseline versus post-nicotine) for GABA [F(2,27)=0.40, p=0.67] or glutamate
[F(2,19)=0.94, p=0.40]. However, there was a significant main effect of treatment group in the
analysis of GABA [F(2,27)= 4.21, p=0.02], an effect that was largely driven by the higher levels of
GABA observed in STZ-treated versus vehicle- and STZ-treated+insulin rats (†p<0.05). Also,
there was a main effect of treatment group in the analysis of glutamate [F(2,19)= 3.56, p=0.04], with
STZ-treated rats displaying lower levels of glutamate relative to vehicle- and STZ-treated+insulin
rats (†p<0.05). Lastly, there was an interaction between treatment group by sampling condition
(baseline versus post-nicotine) for ACh [F(2,25)=3.41, p=0.04], with STZ-treated rats displaying
lower ACh levels versus vehicle- and STZ-treated+insulin rats (†p<0.05). Moreover, vehicletreated rats displayed higher ACh levels post-nicotine as compared to baseline (ꞵp<0.05). Overall,
there were no differences in the analysis of dopamine, GABA, glutamate, or ACh levels in the
NAc of vehicle- and STZ-treated+insulin rats.
3.4 Neurotransmitter levels in the VTA
Figure 3 illustrates mean neurotransmitter levels (nM±SEM) in the VTA across time (left
panels) and collapsed across baseline and post-nicotine samples (right panels). The analyses of
dopamine levels across time revealed that there was no interaction between treatment group and
time [F(19.18,267.54)=0.92, p=0.56]. However, there was a significant main effect of treatment
[F(2,27)=20.17, p=0.0001], with STZ-treated rats displaying lower levels of dopamine relative to
vehicle- and STZ-treated+insulin rats (†p<0.05). The analysis of dopamine levels in the right panel
revealed an interaction between treatment group and sampling condition (baseline versus postnicotine) [F(2,27)= 3.48, p=0.04]. Nicotine produced an increase in dopamine levels relative to
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baseline in STZ-treated+insulin rats (ꞵp<0.05). Also, STZ-treated rats displayed lower levels of
dopamine relative to vehicle- and STZ-treated+insulin rats during baseline and following nicotine
administration (†p<0.05).
Subsequent analyses of changes in neurotransmitter levels across time revealed that there
was no interaction between treatment group and time for GABA [F(14.28,171.37)=1.34, p=0.27],
glutamate [F(6.53,65.31)=0.57, p=0.76], and ACh [F(10.42,130.29)=0.46, p=0.92]. There were significant
main effects of treatment group in the analysis of GABA [F(2,24)=18.23, p=0.0001] and glutamate
[F(2,20)=4.26, p=0.02]. Specifically, STZ-treated rats displayed higher levels of GABA and lower
levels of glutamate relative to vehicle- and STZ-treated+insulin rats (†p<0.05). The analysis of
GABA in the right panel revealed an interaction between treatment group and sampling condition
(baseline versus post-nicotine) for GABA [F(2,24)=3.88, p=0.035]. Nicotine produced an increase
in GABA levels relative to baseline in vehicle- and STZ-treated groups of rats (ꞵp<0.05). Also,
after nicotine administration, STZ-treated rats displayed higher levels of GABA relative to vehicleand STZ-treated+insulin rats (†p<0.05). The analysis of glutamate levels in the right panel revealed
that there was no interaction between treatment group and sampling condition (baseline versus
post-nicotine) for glutamate [F(2,20)=0.51, p=0.60]. In contrast, there was a main effect of treatment
group in the analysis of glutamate [F(2,20)=.8.94, p=0.002], with STZ-treated rats displaying lower
levels of glutamate relative to vehicle- and STZ-treated+insulin rats (†p<0.05). The analyses of
ACh revealed that there was no interaction between treatment group and sampling condition
(baseline versus post-nicotine) [F(2,25)=0.65, p=0.52] and no main effect of treatment group
[F(2,25)= 1.93, p=0.16]. Overall, there were no differences in the analysis of dopamine, GABA,
glutamate, or ACh levels in the VTA of vehicle- and STZ-treated+insulin rats.
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3.5 Dopamine levels following intra-VTA bicuculline
Figure 4 illustrates mean dopamine levels (nM±SEM) in the NAc following intra-VTA
administration of bicuculline. The analysis revealed a significant interaction between treatment
and time [F(7.09, 95.84)=7.49, p=0.0001], with STZ-treated rats displaying lower levels of dopamine
at the 20-, and 40- min sampling periods relative to both vehicle- and STZ-treated+insulin rats
(†p<0.05). Also, STZ-treated rats displayed lower dopamine levels at the 60-min sampling period
relative to STZ-treated+insulin rats (#p<0.05).

21

Chapter 4: Discussion
4.1 Summary
The STZ-treated rats in the present study displayed some of the hallmark symptoms of
diabetes, including an increase in glucose levels and a decrease in body weight. The STZ-induced
changes in glucose levels and body weight were restored to control levels following insulin
supplementation. Figure 5 depicts a summary of the neurochemical effects of nicotine in vehicleand STZ-treated rats. Briefly, vehicle-treated rats displayed an increase in NAc dopamine levels
following nicotine administration, an effect that was absent in STZ-treated rats. The absence of
nicotine-induced increases in NAc dopamine in STZ-treated rats appeared to be modulated via
amino acids. Specifically, across all sampling conditions, STZ-treated rats displayed overall higher
GABA and lower glutamate levels in the NAc and VTA. Lastly, vehicle-treated rats displayed a
nicotine-induced increase in NAc ACh levels, an effect that was absent in STZ-treated rats. All of
the neurochemical effects produced by STZ were restored to control levels following insulin
supplementation, with the exception of ACh levels in the VTA.
4.2 Baseline changes
An important consideration is that STZ altered the neurochemical environment prior to
nicotine administration in a region-specific manner. Specifically, in the NAc, the reduction in
insulin produced by STZ did not alter baseline measures of any of the measured neurotransmitters
relative to vehicle-treated controls. In contrast, STZ-treated rats displayed lower baseline levels of
dopamine and glutamate and higher levels of GABA in the VTA as compared to vehicle-treated
controls. These results suggest that a lack of insulin, produced by STZ, results in a tonic reduction
in excitatory glutamate and an increase in inhibitory GABA release in the VTA. The observed
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alterations in baseline levels in the cell body region may have led to the suppression of phasic
release of dopamine in the NAc following nicotine administration.
4.3 Nicotine effects
The largest neurochemical effect of nicotine was observed in the NAc, with control rats
displaying a 2-fold increase in NAc dopamine levels. This nicotine-induced increase in NAc
dopamine was blunted in STZ-treated rats, consistent with previous work (O’Dell et al., 2013).
The present findings expand upon work in the latter study by showing that STZ also reduces
nicotine-induced dopamine release in the cell body region of the VTA. Consistent with our
findings, work in other laboratories has revealed that STZ administration reduced dopamine
synthesis in rat striatal tissue (Trulson and Himmel, 1983; Bitar et al., 1986). Also, STZ
administration has been shown to lower dopamine levels in dialysate samples collected from the
hippocampus (Yamato et al., 2004) and tissue levels in the hypothalamus (Bitar et al., 1986; Chu
et al., 1986). Together, these studies provide converging lines of evidence that a reduction in
insulin levels produced by STZ reduces dopamine transmission in the mesolimbic pathway,
possibly via amino acid regulation of dopamine release as described below.
Prior work has established that the amino acid neurotransmitters GABA and glutamate
regulate dopamine release in the NAc (Qi et al., 2016; Hjelmstad, 2004; Kalivas et al., 1993;
Melchior et al., 2015). Following nicotine administration, the present study revealed that STZtreated rats displayed higher GABA and lower glutamate levels in both the NAc and VTA. Based
on this finding, we suggest that a lack of insulin produced by STZ might have suppressed nicotineinduced dopamine release in the NAc via reduced excitatory and greater inhibitory regulation of
dopamine in the cell body and terminal region of the NAc. Our assertion with regard to reduced
glutamatergic control is supported by previous studies in the hippocampus showing that STZ
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suppresses AMPA-mediated excitatory currents (Sasaki-Hamada et al., 2012), glutamate receptor
expression (Viswaprakash et al., 2015), and extracellular glutamate levels (Reisi et al., 2009).
Also, our assertion with regard to greater GABAergic inhibition may be supported by the finding
that intra-VTA blockade of GABA receptors completely suppressed dopamine transmission in the
A

NAc of STZ-treated rats.
The present study also revealed that vehicle-treated rats displayed an increase in ACh
release in the NAc following nicotine administration, and this effect was absent in STZ-treated
rats. Interestingly, STZ administration did not alter ACh levels in the VTA, suggesting that
neurochemical changes produced by a lack of insulin are primarily focused in the NAc. A previous
report found that intraventricular administration of STZ increased choline acetyltransferase
activity, an effect that was associated with greater clearance of extracellular ACh levels (Naik et
al., 2016). Based on the latter report, it is possible that STZ produced an increase in choline
acetyltransferase levels, and this may have blunted the ability of nicotine to increase ACh levels
in the NAc.
4.4 Insulin restoration
The present study compared baseline measures and the neurochemical effects of nicotine
in rats that received insulin immediately after STZ administration. The results revealed that insulin
prevented the neurochemical changes produced by STZ during baseline and following nicotine
administration. The precise mechanisms by which insulin restores the neurochemical effects of
nicotine in STZ-treated rats remain unclear. One possibility is that the restorative effects of insulin
occur via second messenger signaling pathways. This suggestion is based on a previous report
demonstrating that STZ administration results in lower insulin receptor substrate-2 (IRS-2) and
insulin growth factor-1 receptor β (IGF-1Rβ) expression in the NAc, and these effects were
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restored to control levels following insulin supplementation (Cruz et al., 2019). Prior work has
linked IRS-2 expression to dopamine cell integrity in the VTA, as a down-regulation of IRS-2 in
the VTA has been shown to reduce the size of dopamine cell bodies in the VTA (Russo et al.,
2007). Another possibility is that insulin restores dopamine release in the NAc indirectly via
activation of insulin receptors on cholinergic interneurons. This is based on a prior report showing
that insulin enhances striatal dopamine release via activation of insulin receptors located on
cholinergic interneurons in the NAc (Stouffer et al., 2015). Future studies are needed to more fully
understand the mechanisms by which insulin modulates the neurochemical effects of nicotine in
the mesolimbic pathway of STZ-treated rats.
4.5 Final considerations
The studies in this report involved measurements of different neurotransmitter systems
collected from different brain regions. Future studies will need to examine the causal relationships
between insulin and the amino acid systems that regulate dopamine transmission in the mesolimbic
pathway. Future studies will also need to incorporate other brain regions, such as the medial
habenula where there is high expression of a diabetes-related gene (TCF7L2) that is closely
associated with nicotine intake in rodents (Duncan et al., 2019). Also, the present study normalized
insulin to physiological levels immediately after STZ administration using a protocol that has been
established in rodents (see Hu et al., 1993). The temporal overlap in STZ administration with
insulin restoration in the present study may not reflect the typical onset of diabetes with delayed
clinical interventions involving insulin therapy and/or smoking cessation medications. Thus, future
studies are needed to examine whether our observed neurochemical effects persist in STZ-treated
rats that are supplemented with insulin, as might occur in a clinical situation. This work might also
assess whether smoking cessation medications that enhance dopamine transmission reduce
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nicotine intake in rodent models of diabetes. This work will be important towards understanding
the underlying mechanisms that promote greater nicotine use in persons with diabetes.
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Figure 1. Mean (±SEM) body weight (top panel) and glucose levels (bottom panel) in vehicletreated (open circles), STZ-treated (black circles), and STZ-treated+insulin rats (gray circles). The
daggers (†) denotes a difference from vehicle-treated and STZ-treated+insulin rats (p ≤ 0.05).
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Figure 2. NAc dialysate levels of dopamine, GABA, glutamate, and ACh levels during baseline
and following nicotine administration. The panels on the left reflect each 20-min sampling period,
and the panels on the right reflect sampling conditions (baseline versus nicotine) in vehicle-treated
(open circles), STZ-treated (black circles), and STZ-treated+insulin (gray circles) rats. Data are
expressed in nM concentrations (±SEM). The asterisk (*) denotes a significant difference from
vehicle-treated rats, the number sign (#) denotes significant difference from STZ-treated+insulin
rats, the (ꞵ) denotes a significant difference from baseline within-group, and the daggers (†) denote
a significant difference from both vehicle-treated and STZ-treated+insulin rats (p ≤ 0.05).
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Figure 3. VTA dialysate levels of dopamine, GABA, glutamate, and ACh levels during baseline
and following nicotine administration. The panels on the left reflect each 20-min sampling period,
and the panels on the right reflect sampling conditions (baseline versus nicotine) in vehicle-treated
(open circles), STZ-treated (black circles), and STZ-treated+insulin (gray circles) rats. Data are
expressed in nM concentrations (±SEM). The (ꞵ) denotes a significant difference from baseline
within-group, and the dagger (†) denotes a significant difference from both vehicle-treated and
STZ-treated+insulin rats (p ≤ 0.05).
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Figure 4. NAc dopamine levels during baseline and following intra-VTA infusion of
bicuculline (100 M) in vehicle-treated (open circles), STZ-treated (black circles), and STZtreated+insulin (gray circles) rats. Data are expressed in nanomolar (nM) concentrations (±SEM).
The number sign (#) denotes significant difference from STZ-treated+insulin rats, and the dagger
(†) denotes a significant difference from both vehicle-treated and STZ-treated+insulin rats (p ≤
0.05).
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Figure 5. The image summarizes the neurochemical effects of nicotine in the mesolimbic pathway
of vehicle- and STZ-treated rats. In STZ-treated rats, nicotine-induced increases in NAc dopamine
are blunted as compared to vehicle-treated rats. It is hypothesized that the latter effect is mediated
via greater GABA inhibition (larger minus sign) and reduced glutamate excitation (smaller plus
sign) in STZ-treated rats. Importantly, STZ-induced neurochemical changes were restored to
vehicle-treated control levels following insulin supplementation (Abbreviations: acetylcholine;
ACh; gamma-amino butyric acid; GABA; medium spiny neuron; MSN).
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